<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922037</url>
  </required_header>
  <id_info>
    <org_study_id>ML28528</org_study_id>
    <nct_id>NCT01922037</nct_id>
  </id_info>
  <brief_title>A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)</brief_title>
  <official_title>A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, prospective study will evaluate the baseline participant characteristics
      (including biomarkers) associated with a variety of individual and composite clinical
      outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2013</start_date>
  <completion_date type="Actual">March 31, 2016</completion_date>
  <primary_completion_date type="Actual">March 31, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Asthma Exacerbations During Months 1-12</measure>
    <time_frame>Months 1-12</time_frame>
    <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma Exacerbations During Months 1-6</measure>
    <time_frame>Months 1-6</time_frame>
    <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/=3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma Exacerbations During Months 7-12</measure>
    <time_frame>Months 7-12</time_frame>
    <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Hospital Admissions During Months 1-12</measure>
    <time_frame>Months 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Hospital Admissions During Months 1-6</measure>
    <time_frame>Months 1-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Hospital Admissions During Months 7-12</measure>
    <time_frame>Months 7-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related ER Visits During Months 1-12</measure>
    <time_frame>Months 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Emergency Room (ER) Visits During Months 1-6</measure>
    <time_frame>Months 1-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related ER Visits During Months 7-12</measure>
    <time_frame>Months 7-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-12</measure>
    <time_frame>Months 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-6</measure>
    <time_frame>Months 1-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 7-12</measure>
    <time_frame>Months 7-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-12</measure>
    <time_frame>Months 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-6</measure>
    <time_frame>Months 1-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 7-12</measure>
    <time_frame>Months 7-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Number of Asthma Exacerbations</measure>
    <time_frame>Months 1-12</time_frame>
    <description>Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, &gt;/=4) was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Number of Asthma Exacerbations Requiring Treatment With Systemic Steroids</measure>
    <time_frame>Months 1-12</time_frame>
    <description>Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, &gt;/=4) requiring treatment with systemic steroids was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Raw Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline, Month 6, end of study (EOS)/early termination (ET) (up to Month 12)</time_frame>
    <description>FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. Pre-bronchodilator FEV1 and post-bronchodilator FEV1 are reported for each timepoint. FEV1 was measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Raw Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
    <description>FVC was defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pre-bronchodilator FVC and post-bronchodilator FVC are reported for each timepoint. FVC was measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Raw Forced Expiratory Flow at 25-75 Percent (%) of Pulmonary Volume (FEF25%âˆ’75%)</measure>
    <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
    <description>FEF25%-75% was defined as the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Pre-bronchodilator FEF25%-75% and post-bronchodilator FEF25%-75% are reported for each timepoint. FEF25%-75% was measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage Predicted FEV1 (ppFEV1)</measure>
    <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
    <description>FEV1 is the volume of air that can be forced out in one second after taking a deep breath, as measured using spirometry. Hankinson and Wang standards were used to calculate ppFEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. ppFEV1= 100 multiplied by (*) FEV1 (in liters [L]) divided by (/) predicted FEV1 (in L). Pre-bronchodilator ppFEV1 and post-bronchodilator ppFEV1 are reported for each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Prior Asthma Medications by Category or Class of Medications</measure>
    <time_frame>Baseline</time_frame>
    <description>Prior asthma medications were defined as all medications used for asthma prior to the study (initiated within 90 days of baseline) and were assessed retrospectively at baseline. Participants received prior asthma medications of following categories or classes: short acting beta agonist (SABA), combination inhaled corticosteroids/long acting beta agonist (ICS/LABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (ICS), oral/parenteral (systemic) corticosteroids, anticholinergic, long acting beta agonist (LABA), and other medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Concomitant and Ongoing Asthma Medications by Category or Class of Medications</measure>
    <time_frame>Baseline until EOS/ET (up to Month 12)</time_frame>
    <description>Concomitant and ongoing asthma medications were defined as all medications used for asthma which began on or after the participant's study start, as well as those ongoing at the beginning of the study. Participants received following categories or classes of concomitant and ongoing asthma medications: SABA, combination ICS/LABA, LTRA, oral/parenteral (systemic) corticosteroids, ICS, anticholinergic, LABA, and other medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) Overall Score</measure>
    <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
    <description>AQLQ +12 is a 32-item disease specific questionnaire designed to assess the participants' asthma-specific health-related quality of life (QOL). The questionnaire contains four domains: activity limitations (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). All items are scored on a 7-point likert scale. All item scores are averaged to produce one overall QOL score. Overall score ranges from 1 (total impairment) to 7 (no impairment), with higher scores indicating better QOL. A positive change from baseline indicated improved QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Test (ACT) Overall Score</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12</time_frame>
    <description>Multidimensional factors associated with asthma control from the participant's perspective were assessed using the ACT questionnaire. The ACT is a validated, five-item patient-reported outcome (PRO) questionnaire that measures the impact of asthma on home and work activities, shortness of breath, symptoms, rescue medication usage, and overall asthma control. All items are scored on a 5-point likert scale (1 to 5). All item scores are added together to calculate a total score. Total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. A positive change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score</measure>
    <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
    <description>WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity. A negative change in score indicated improvement and a positive change indicated impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using Global Evaluation of Treatment Effectiveness (GETE) by Inversigator</measure>
    <time_frame>EOS/ET (up to Month 12)</time_frame>
    <description>Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by investigator, is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using GETE by Participant</measure>
    <time_frame>EOS/ET (up to Month 12)</time_frame>
    <description>Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by participant, is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Quality of Life Score</measure>
    <time_frame>Baseline, EOS/ET (up to Month 12)</time_frame>
    <description>The MiniRQLQ is a shorter version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) instrument. The MiniRQLQ is a validated quality of life questionnaire to measure the functional impairments that are most troublesome to adult participants with either seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. The miniRQLQ contains 14 items; each item scored on a 7-point scale ranging from 0 [not impaired at all] to 6 [severely impaired]). The overall quality of life score is the average of the all item scores and ranges from 0 (not impaired at all) to 6 (severely impaired), with higher scores indicating more impairment. A negative change in score indicated improvement and a positive change indicated impairment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">806</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Participants With Allergic Asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.</description>
    <arm_group_label>Participants With Allergic Asthma</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants identified by the investigator as a candidate for treatment for asthma
             with omalizumab

          -  Confirmation of access to omalizumab through insurance or other source of funding

        Exclusion Criteria:

          -  Enrollment in any other concurrent clinical trial or observational study

          -  Participants for whom omalizumab treatment is contraindicated

          -  Participants who had a prior allergic reaction to omalizumab or its excipients

          -  Participants treated with omalizumab within the previous year

          -  Participants who received an experimental drug as part of another study within 3
             months of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Allergy &amp; Asthma</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsville Lung Associates PC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Tan Allergy &amp; Asthma</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234-2966</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dedicated Clinical Research</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Allergy &amp; Asthma; Clinical Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stuart Epstein MD - PP</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials Global, LLC</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Allergy Associates</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allianz Medical and Research Center</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Ebbeling MD - PP</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg Medical Clinic</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Inst Valley</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Care Ctr, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Allergy &amp; Asthma; Medical Assoc</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choc Psf, Amc</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Allergy &amp; Asthma Medical Group, Inc.</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <zip>93551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joann Blessing-Moore MD - PP</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TPMG - Rancho Cordova</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redding Allergy &amp; Asthma Care</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Consultants</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Allergy Resp Dis Ctr</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Allergy and Asthma</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Assoc Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Allergy and Asthma Clinic</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Medical Group; Clinical Research Division</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christopher C Randolph MD - PP</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterbury Pulmonary Associates</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Sleep; Allergy &amp; Lung Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAADRS; Clinical Research Center</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Immun Center</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Ctr-Allergy &amp; Asthma</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FL Ctr Allergy &amp; Asthma Res</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Care of FL; Clinical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Grou</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Sinus Center</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Allergy Center, P.A.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Asthma Allergy &amp; Immun; Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Pollens</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookstone Clinical Res Ctr</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Care Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aeroallergy Research Labs</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy of Idaho</name>
      <address>
        <city>Twin Falls</city>
        <state>Idaho</state>
        <zip>83301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Medicine Consultants</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Care LTD</name>
      <address>
        <city>Glen Carbon</city>
        <state>Illinois</state>
        <zip>62034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze Wheeze and Itch Associates LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Care</name>
      <address>
        <city>Crown Point</city>
        <state>Indiana</state>
        <zip>46307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Allergy and Asthma Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy And Asthma Assoc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abraham Research PLLC</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asth Phys of Cent KY</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Paul Shapero</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Clinical Research Inc - CRN</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenn M. Silber, M.D., P.A</name>
      <address>
        <city>Ellicott City</city>
        <state>Maryland</state>
        <zip>21042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy &amp; Asthma</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20878</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>98410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research.</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Arth Fam Treatment Ctr</name>
      <address>
        <city>Gardner</city>
        <state>Massachusetts</state>
        <zip>01440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Medical Research Inc</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGovern &amp; Baja Allergy Assoc</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Inst of MI</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Allergy Ctr of SW MI</name>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <zip>49024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Inst</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ. School of Med</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Allergy &amp; Resp Res Ctr</name>
      <address>
        <city>Brick Township</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Ped Aller Central Jersey</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Asthma and Allergy</name>
      <address>
        <city>Highland Park</city>
        <state>New Jersey</state>
        <zip>08904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Allergy Asthma Immunology Associates</name>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Treatment Center of New Jersey</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Allergy Associates</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Consultants, PA</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boris Sagalovich MD - PC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Medical Research Pc</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Medical Arts, LLP</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop Univ Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and ISAAC Perlmutter Cancer Center at NYU Langone.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parikh Institute for Research LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert P Hirdt DO - PP</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <zip>12550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olean Medical Group</name>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <zip>14760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Allergy &amp; Asthma PLLC</name>
      <address>
        <city>Rockville Center</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urban Health Plan, Inc.</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan Kaufman MD - PP</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Partners of Western NC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Centre of Dayton</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santiago Reyes MD-Private Prac</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clin Res Pc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bend Memorial Clinic</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central PA Asth &amp; Allergy Care; Research Division</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthmas; Specialists of Harrisburg</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Group</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst for Resp &amp; Sleep Med PC</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Research of NJ, lnc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Clinical Immun Assoc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Hills Pulmonary Assoc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Specialists</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nat'l Aller Asth-Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ADAC Research PA</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharma Research</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Austin Allergy Asthma and Immunology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elliot J. Ginchansky, MD, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Research Assoc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch;Division of APICS</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Immun Assoc</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Live Oak Allergy &amp; Asthma Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Res Ctr PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugar Land Allerg Asthma Immun</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of Utah</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgerland Clinical Research</name>
      <address>
        <city>North Logan</city>
        <state>Utah</state>
        <zip>84341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Research of Albingdon</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan, LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Sinus Center</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughter</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellingham Asthma, Allergy &amp; Immunology</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASTHMA, Inc</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Sleep Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Asthma Allergy Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Sinus Center</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin;Allergy &amp; Asthma Clinical Research</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <results_first_submitted>November 9, 2017</results_first_submitted>
  <results_first_submitted_qc>November 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Results are reported by age group (adult participants and adolescent participants) as well as for all participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
          <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
        <group group_id="P2">
          <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
          <description>Adult participants (age greater than or equal to [&gt;/=18] years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="737"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="732"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="563"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator/Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other unspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
          <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
        <group group_id="B2">
          <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
          <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="737"/>
            <count group_id="B3" value="806"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.0" spread="1.69"/>
                    <measurement group_id="B2" value="50.4" spread="14.75"/>
                    <measurement group_id="B3" value="47.3" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>All enrolled participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="487"/>
                    <measurement group_id="B3" value="512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Asthma Exacerbations During Months 1-12</title>
        <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma Exacerbations During Months 1-12</title>
          <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.815"/>
                    <measurement group_id="O2" value="0.81" spread="1.407"/>
                    <measurement group_id="O3" value="0.78" spread="1.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma Exacerbations During Months 1-6</title>
        <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/=3 days.</description>
        <time_frame>Months 1-6</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma Exacerbations During Months 1-6</title>
          <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/=3 days.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.440"/>
                    <measurement group_id="O2" value="0.51" spread="0.988"/>
                    <measurement group_id="O3" value="0.48" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma Exacerbations During Months 7-12</title>
        <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
        <time_frame>Months 7-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma Exacerbations During Months 7-12</title>
          <description>An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.521"/>
                    <measurement group_id="O2" value="0.35" spread="0.756"/>
                    <measurement group_id="O3" value="0.35" spread="0.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Hospital Admissions During Months 1-12</title>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Hospital Admissions During Months 1-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related hospital admissions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.205"/>
                    <measurement group_id="O2" value="0.06" spread="0.356"/>
                    <measurement group_id="O3" value="0.06" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Hospital Admissions During Months 1-6</title>
        <time_frame>Months 1-6</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Hospital Admissions During Months 1-6</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related hospital admissions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.169"/>
                    <measurement group_id="O2" value="0.03" spread="0.230"/>
                    <measurement group_id="O3" value="0.03" spread="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Hospital Admissions During Months 7-12</title>
        <time_frame>Months 7-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Hospital Admissions During Months 7-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related hospital admissions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.126"/>
                    <measurement group_id="O2" value="0.03" spread="0.215"/>
                    <measurement group_id="O3" value="0.03" spread="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related ER Visits During Months 1-12</title>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related ER Visits During Months 1-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related ER visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.380"/>
                    <measurement group_id="O2" value="0.14" spread="0.575"/>
                    <measurement group_id="O3" value="0.14" spread="0.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Emergency Room (ER) Visits During Months 1-6</title>
        <time_frame>Months 1-6</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Emergency Room (ER) Visits During Months 1-6</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related ER visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.205"/>
                    <measurement group_id="O2" value="0.09" spread="0.410"/>
                    <measurement group_id="O3" value="0.09" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related ER Visits During Months 7-12</title>
        <time_frame>Months 7-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related ER Visits During Months 7-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related ER visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.296"/>
                    <measurement group_id="O2" value="0.06" spread="0.293"/>
                    <measurement group_id="O3" value="0.06" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-12</title>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related physician's office visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.771"/>
                    <measurement group_id="O2" value="0.39" spread="0.866"/>
                    <measurement group_id="O3" value="0.39" spread="0.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-6</title>
        <time_frame>Months 1-6</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-6</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related physician's office visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.598"/>
                    <measurement group_id="O2" value="0.23" spread="0.584"/>
                    <measurement group_id="O3" value="0.23" spread="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 7-12</title>
        <time_frame>Months 7-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 7-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related physician's office visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.423"/>
                    <measurement group_id="O2" value="0.18" spread="0.515"/>
                    <measurement group_id="O3" value="0.18" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-12</title>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related telephone calls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.783"/>
                    <measurement group_id="O2" value="0.43" spread="1.181"/>
                    <measurement group_id="O3" value="0.43" spread="1.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-6</title>
        <time_frame>Months 1-6</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-6</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related telephone calls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.407"/>
                    <measurement group_id="O2" value="0.24" spread="0.799"/>
                    <measurement group_id="O3" value="0.23" spread="0.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 7-12</title>
        <time_frame>Months 7-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 7-12</title>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>asthma-related telephone calls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.544"/>
                    <measurement group_id="O2" value="0.22" spread="0.692"/>
                    <measurement group_id="O3" value="0.22" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Number of Asthma Exacerbations</title>
        <description>Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, &gt;/=4) was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Number of Asthma Exacerbations</title>
          <description>Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, &gt;/=4) was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No (0) Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="61.8"/>
                    <measurement group_id="O3" value="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="18.3"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Asthma Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Asthma Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/=4 Asthma Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Number of Asthma Exacerbations Requiring Treatment With Systemic Steroids</title>
        <description>Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, &gt;/=4) requiring treatment with systemic steroids was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
        <time_frame>Months 1-12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Number of Asthma Exacerbations Requiring Treatment With Systemic Steroids</title>
          <description>Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, &gt;/=4) requiring treatment with systemic steroids was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for &gt;/= 3 days.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No (0) Asthma Exacerbation Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0"/>
                    <measurement group_id="O2" value="62.3"/>
                    <measurement group_id="O3" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Asthma Exacerbation Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Asthma Exacerbations Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Asthma Exacerbations Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/=4 Asthma Exacerbations Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Raw Forced Expiratory Volume in One Second (FEV1)</title>
        <description>FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. Pre-bronchodilator FEV1 and post-bronchodilator FEV1 are reported for each timepoint. FEV1 was measured using spirometry.</description>
        <time_frame>Baseline, Month 6, end of study (EOS)/early termination (ET) (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Raw Forced Expiratory Volume in One Second (FEV1)</title>
          <description>FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. Pre-bronchodilator FEV1 and post-bronchodilator FEV1 are reported for each timepoint. FEV1 was measured using spirometry.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="728"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Pre-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="728"/>
                    <count group_id="O3" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="0.736"/>
                    <measurement group_id="O2" value="2.24" spread="0.820"/>
                    <measurement group_id="O3" value="2.27" spread="0.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6: Pre-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="568"/>
                    <count group_id="O3" value="626"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.402"/>
                    <measurement group_id="O2" value="0.06" spread="0.359"/>
                    <measurement group_id="O3" value="0.06" spread="0.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET: Pre-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="573"/>
                    <count group_id="O3" value="630"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.463"/>
                    <measurement group_id="O2" value="0.03" spread="0.378"/>
                    <measurement group_id="O3" value="0.04" spread="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Post-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.767"/>
                    <measurement group_id="O2" value="2.38" spread="0.810"/>
                    <measurement group_id="O3" value="2.41" spread="0.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6: Post-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="523"/>
                    <count group_id="O3" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.522"/>
                    <measurement group_id="O2" value="0.04" spread="0.286"/>
                    <measurement group_id="O3" value="0.05" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET: Post-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="534"/>
                    <count group_id="O3" value="586"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.446"/>
                    <measurement group_id="O2" value="0.02" spread="0.322"/>
                    <measurement group_id="O3" value="0.03" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Raw Forced Vital Capacity (FVC)</title>
        <description>FVC was defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pre-bronchodilator FVC and post-bronchodilator FVC are reported for each timepoint. FVC was measured using spirometry.</description>
        <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Raw Forced Vital Capacity (FVC)</title>
          <description>FVC was defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pre-bronchodilator FVC and post-bronchodilator FVC are reported for each timepoint. FVC was measured using spirometry.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="728"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Pre-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="728"/>
                    <count group_id="O3" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="0.842"/>
                    <measurement group_id="O2" value="3.08" spread="0.987"/>
                    <measurement group_id="O3" value="3.11" spread="0.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6: Pre-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="568"/>
                    <count group_id="O3" value="625"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.380"/>
                    <measurement group_id="O2" value="0.07" spread="0.562"/>
                    <measurement group_id="O3" value="0.07" spread="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET: Pre-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="572"/>
                    <count group_id="O3" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.321"/>
                    <measurement group_id="O2" value="0.03" spread="0.417"/>
                    <measurement group_id="O3" value="0.04" spread="0.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Post-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="0.878"/>
                    <measurement group_id="O2" value="3.19" spread="0.959"/>
                    <measurement group_id="O3" value="3.21" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6: Post-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="523"/>
                    <count group_id="O3" value="576"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.324"/>
                    <measurement group_id="O2" value="0.07" spread="0.661"/>
                    <measurement group_id="O3" value="0.07" spread="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET: Post-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="533"/>
                    <count group_id="O3" value="585"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.301"/>
                    <measurement group_id="O2" value="0.02" spread="0.349"/>
                    <measurement group_id="O3" value="0.04" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Raw Forced Expiratory Flow at 25-75 Percent (%) of Pulmonary Volume (FEF25%âˆ’75%)</title>
        <description>FEF25%-75% was defined as the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Pre-bronchodilator FEF25%-75% and post-bronchodilator FEF25%-75% are reported for each timepoint. FEF25%-75% was measured using spirometry.</description>
        <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Raw Forced Expiratory Flow at 25-75 Percent (%) of Pulmonary Volume (FEF25%âˆ’75%)</title>
          <description>FEF25%-75% was defined as the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Pre-bronchodilator FEF25%-75% and post-bronchodilator FEF25%-75% are reported for each timepoint. FEF25%-75% was measured using spirometry.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>liters per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Pre-bronchodilator FEF25%âˆ’75%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="727"/>
                    <count group_id="O3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="12.328"/>
                    <measurement group_id="O2" value="2.28" spread="9.646"/>
                    <measurement group_id="O3" value="2.42" spread="9.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6:Pre-bronchodilator FEF25%âˆ’75%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="564"/>
                    <count group_id="O3" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="13.518"/>
                    <measurement group_id="O2" value="-0.44" spread="10.868"/>
                    <measurement group_id="O3" value="-0.55" spread="11.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET:Pre-bronchodilator FEF25%âˆ’75%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="568"/>
                    <count group_id="O3" value="625"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="13.426"/>
                    <measurement group_id="O2" value="-0.47" spread="10.825"/>
                    <measurement group_id="O3" value="-0.58" spread="11.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Post-bronchodilator FEF25%âˆ’75%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="777"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="6.676"/>
                    <measurement group_id="O2" value="2.58" spread="9.503"/>
                    <measurement group_id="O3" value="2.68" spread="9.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6:Post-bronchodilator FEF25%âˆ’75%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="518"/>
                    <count group_id="O3" value="571"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="7.513"/>
                    <measurement group_id="O2" value="-0.59" spread="11.051"/>
                    <measurement group_id="O3" value="-0.63" spread="10.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET:Post-bronchodilator FEF25%âˆ’75%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="530"/>
                    <count group_id="O3" value="582"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="7.515"/>
                    <measurement group_id="O2" value="-0.61" spread="10.926"/>
                    <measurement group_id="O3" value="-0.62" spread="10.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage Predicted FEV1 (ppFEV1)</title>
        <description>FEV1 is the volume of air that can be forced out in one second after taking a deep breath, as measured using spirometry. Hankinson and Wang standards were used to calculate ppFEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. ppFEV1= 100 multiplied by (*) FEV1 (in liters [L]) divided by (/) predicted FEV1 (in L). Pre-bronchodilator ppFEV1 and post-bronchodilator ppFEV1 are reported for each timepoint.</description>
        <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage Predicted FEV1 (ppFEV1)</title>
          <description>FEV1 is the volume of air that can be forced out in one second after taking a deep breath, as measured using spirometry. Hankinson and Wang standards were used to calculate ppFEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. ppFEV1= 100 multiplied by (*) FEV1 (in liters [L]) divided by (/) predicted FEV1 (in L). Pre-bronchodilator ppFEV1 and post-bronchodilator ppFEV1 are reported for each timepoint.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="728"/>
                <count group_id="O3" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Pre-bronchodilator ppFEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="728"/>
                    <count group_id="O3" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.89" spread="16.934"/>
                    <measurement group_id="O2" value="74.23" spread="20.569"/>
                    <measurement group_id="O3" value="75.38" spread="20.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6: Pre-bronchodilator ppFEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="568"/>
                    <count group_id="O3" value="626"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="13.279"/>
                    <measurement group_id="O2" value="1.77" spread="12.270"/>
                    <measurement group_id="O3" value="1.86" spread="12.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET: Pre-bronchodilator ppFEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="573"/>
                    <count group_id="O3" value="630"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="14.713"/>
                    <measurement group_id="O2" value="0.91" spread="12.922"/>
                    <measurement group_id="O3" value="1.37" spread="13.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Post-bronchodilator ppFEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.61" spread="16.416"/>
                    <measurement group_id="O2" value="78.92" spread="19.514"/>
                    <measurement group_id="O3" value="80.15" spread="19.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6: Post-bronchodilator ppFEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="523"/>
                    <count group_id="O3" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="16.398"/>
                    <measurement group_id="O2" value="1.47" spread="9.617"/>
                    <measurement group_id="O3" value="1.52" spread="10.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET: Post-bronchodilator ppFEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="534"/>
                    <count group_id="O3" value="586"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="14.673"/>
                    <measurement group_id="O2" value="0.82" spread="11.099"/>
                    <measurement group_id="O3" value="1.40" spread="11.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Prior Asthma Medications by Category or Class of Medications</title>
        <description>Prior asthma medications were defined as all medications used for asthma prior to the study (initiated within 90 days of baseline) and were assessed retrospectively at baseline. Participants received prior asthma medications of following categories or classes: short acting beta agonist (SABA), combination inhaled corticosteroids/long acting beta agonist (ICS/LABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (ICS), oral/parenteral (systemic) corticosteroids, anticholinergic, long acting beta agonist (LABA), and other medication.</description>
        <time_frame>Baseline</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Prior Asthma Medications by Category or Class of Medications</title>
          <description>Prior asthma medications were defined as all medications used for asthma prior to the study (initiated within 90 days of baseline) and were assessed retrospectively at baseline. Participants received prior asthma medications of following categories or classes: short acting beta agonist (SABA), combination inhaled corticosteroids/long acting beta agonist (ICS/LABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (ICS), oral/parenteral (systemic) corticosteroids, anticholinergic, long acting beta agonist (LABA), and other medication.</description>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="737"/>
                <count group_id="O3" value="806"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="99.3"/>
                    <measurement group_id="O3" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="88.6"/>
                    <measurement group_id="O3" value="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combination ICS/LABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7"/>
                    <measurement group_id="O2" value="84.1"/>
                    <measurement group_id="O3" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTRA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9"/>
                    <measurement group_id="O2" value="66.6"/>
                    <measurement group_id="O3" value="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral/Parenteral (systemic) corticisteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="31.6"/>
                    <measurement group_id="O3" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anticholinergic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Concomitant and Ongoing Asthma Medications by Category or Class of Medications</title>
        <description>Concomitant and ongoing asthma medications were defined as all medications used for asthma which began on or after the participantâ€™s study start, as well as those ongoing at the beginning of the study. Participants received following categories or classes of concomitant and ongoing asthma medications: SABA, combination ICS/LABA, LTRA, oral/parenteral (systemic) corticosteroids, ICS, anticholinergic, LABA, and other medication.</description>
        <time_frame>Baseline until EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Concomitant and Ongoing Asthma Medications by Category or Class of Medications</title>
          <description>Concomitant and ongoing asthma medications were defined as all medications used for asthma which began on or after the participantâ€™s study start, as well as those ongoing at the beginning of the study. Participants received following categories or classes of concomitant and ongoing asthma medications: SABA, combination ICS/LABA, LTRA, oral/parenteral (systemic) corticosteroids, ICS, anticholinergic, LABA, and other medication.</description>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="737"/>
                <count group_id="O3" value="806"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="99.2"/>
                    <measurement group_id="O3" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="89.4"/>
                    <measurement group_id="O3" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combination ICS/LABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="82.4"/>
                    <measurement group_id="O3" value="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTRA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="63.9"/>
                    <measurement group_id="O3" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral/Parenteral (systemic) corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="34.3"/>
                    <measurement group_id="O3" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anticholinergic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="32.6"/>
                    <measurement group_id="O3" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) Overall Score</title>
        <description>AQLQ +12 is a 32-item disease specific questionnaire designed to assess the participantsâ€™ asthma-specific health-related quality of life (QOL). The questionnaire contains four domains: activity limitations (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). All items are scored on a 7-point likert scale. All item scores are averaged to produce one overall QOL score. Overall score ranges from 1 (total impairment) to 7 (no impairment), with higher scores indicating better QOL. A positive change from baseline indicated improved QOL.</description>
        <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) Overall Score</title>
          <description>AQLQ +12 is a 32-item disease specific questionnaire designed to assess the participantsâ€™ asthma-specific health-related quality of life (QOL). The questionnaire contains four domains: activity limitations (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). All items are scored on a 7-point likert scale. All item scores are averaged to produce one overall QOL score. Overall score ranges from 1 (total impairment) to 7 (no impairment), with higher scores indicating better QOL. A positive change from baseline indicated improved QOL.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="732"/>
                <count group_id="O3" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="732"/>
                    <count group_id="O3" value="801"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="1.332"/>
                    <measurement group_id="O2" value="3.93" spread="1.348"/>
                    <measurement group_id="O3" value="4.00" spread="1.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="593"/>
                    <count group_id="O3" value="652"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.134"/>
                    <measurement group_id="O2" value="1.18" spread="1.223"/>
                    <measurement group_id="O3" value="1.16" spread="1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="603"/>
                    <count group_id="O3" value="666"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="1.174"/>
                    <measurement group_id="O2" value="1.33" spread="1.267"/>
                    <measurement group_id="O3" value="1.31" spread="1.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Control Test (ACT) Overall Score</title>
        <description>Multidimensional factors associated with asthma control from the participantâ€™s perspective were assessed using the ACT questionnaire. The ACT is a validated, five-item patient-reported outcome (PRO) questionnaire that measures the impact of asthma on home and work activities, shortness of breath, symptoms, rescue medication usage, and overall asthma control. All items are scored on a 5-point likert scale (1 to 5). All item scores are added together to calculate a total score. Total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. A positive change from baseline indicated improvement.</description>
        <time_frame>Baseline, Months 3, 6, 9, 12</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Control Test (ACT) Overall Score</title>
          <description>Multidimensional factors associated with asthma control from the participantâ€™s perspective were assessed using the ACT questionnaire. The ACT is a validated, five-item patient-reported outcome (PRO) questionnaire that measures the impact of asthma on home and work activities, shortness of breath, symptoms, rescue medication usage, and overall asthma control. All items are scored on a 5-point likert scale (1 to 5). All item scores are added together to calculate a total score. Total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. A positive change from baseline indicated improvement.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="732"/>
                <count group_id="O3" value="800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="732"/>
                    <count group_id="O3" value="800"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" spread="5.117"/>
                    <measurement group_id="O2" value="13.71" spread="4.910"/>
                    <measurement group_id="O3" value="13.94" spread="4.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="718"/>
                    <count group_id="O3" value="784"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="4.141"/>
                    <measurement group_id="O2" value="3.58" spread="4.263"/>
                    <measurement group_id="O3" value="3.54" spread="4.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="4.339"/>
                    <measurement group_id="O2" value="4.16" spread="4.677"/>
                    <measurement group_id="O3" value="4.11" spread="4.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="4.844"/>
                    <measurement group_id="O2" value="4.39" spread="4.910"/>
                    <measurement group_id="O3" value="4.35" spread="4.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="4.997"/>
                    <measurement group_id="O2" value="4.48" spread="4.926"/>
                    <measurement group_id="O3" value="4.43" spread="4.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score</title>
        <description>WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity. A negative change in score indicated improvement and a positive change indicated impairment.</description>
        <time_frame>Baseline, Month 6, EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score</title>
          <description>WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity. A negative change in score indicated improvement and a positive change indicated impairment.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="717"/>
                <count group_id="O3" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Work time missed: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="401"/>
                    <count group_id="O3" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.37" spread="14.759"/>
                    <measurement group_id="O2" value="7.70" spread="19.936"/>
                    <measurement group_id="O3" value="7.72" spread="19.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work time missed: Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="297"/>
                    <count group_id="O3" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="-3.31" spread="19.796"/>
                    <measurement group_id="O3" value="-3.30" spread="19.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work time missed: Change at EOS/ET</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.27"/>
                    <measurement group_id="O2" value="-4.06" spread="21.977"/>
                    <measurement group_id="O3" value="-4.14" spread="21.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impairment while working: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="397"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="14.142"/>
                    <measurement group_id="O2" value="31.36" spread="27.111"/>
                    <measurement group_id="O3" value="31.15" spread="27.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impairment while working: Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.000"/>
                    <measurement group_id="O2" value="-16.24" spread="26.775"/>
                    <measurement group_id="O3" value="-16.13" spread="26.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impairment while working: Change at EOS/ET</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.00"/>
                    <measurement group_id="O2" value="-15.93" spread="27.677"/>
                    <measurement group_id="O3" value="-15.98" spread="27.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall WI: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="387"/>
                    <count group_id="O3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.85" spread="25.366"/>
                    <measurement group_id="O2" value="33.59" spread="28.737"/>
                    <measurement group_id="O3" value="33.49" spread="28.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall WI: Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="284"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="-15.55" spread="27.476"/>
                    <measurement group_id="O3" value="-15.49" spread="27.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall WI: Change at EOS/ET</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="286"/>
                    <count group_id="O3" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.09"/>
                    <measurement group_id="O2" value="-16.24" spread="29.578"/>
                    <measurement group_id="O3" value="-16.35" spread="29.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity impairment: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="717"/>
                    <count group_id="O3" value="784"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.12" spread="27.577"/>
                    <measurement group_id="O2" value="48.79" spread="28.749"/>
                    <measurement group_id="O3" value="47.70" spread="28.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity impairment: Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="571"/>
                    <count group_id="O3" value="628"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.12" spread="33.449"/>
                    <measurement group_id="O2" value="-19.30" spread="30.445"/>
                    <measurement group_id="O3" value="-18.38" spread="30.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity impairment: Change at EOS/ET</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="577"/>
                    <count group_id="O3" value="635"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.83" spread="31.967"/>
                    <measurement group_id="O2" value="-21.40" spread="32.424"/>
                    <measurement group_id="O3" value="-20.80" spread="32.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using Global Evaluation of Treatment Effectiveness (GETE) by Inversigator</title>
        <description>Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by investigator, is reported.</description>
        <time_frame>EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using Global Evaluation of Treatment Effectiveness (GETE) by Inversigator</title>
          <description>Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by investigator, is reported.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="583"/>
                <count group_id="O3" value="646"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="75.8"/>
                    <measurement group_id="O3" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using GETE by Participant</title>
        <description>Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by participant, is reported.</description>
        <time_frame>EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using GETE by Participant</title>
          <description>Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by participant, is reported.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Quality of Life Score</title>
        <description>The MiniRQLQ is a shorter version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) instrument. The MiniRQLQ is a validated quality of life questionnaire to measure the functional impairments that are most troublesome to adult participants with either seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. The miniRQLQ contains 14 items; each item scored on a 7-point scale ranging from 0 [not impaired at all] to 6 [severely impaired]). The overall quality of life score is the average of the all item scores and ranges from 0 (not impaired at all) to 6 (severely impaired), with higher scores indicating more impairment. A negative change in score indicated improvement and a positive change indicated impairment.</description>
        <time_frame>Baseline, EOS/ET (up to Month 12)</time_frame>
        <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
            <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
            <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Total Participants With Allergic Asthma</title>
            <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Quality of Life Score</title>
          <description>The MiniRQLQ is a shorter version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) instrument. The MiniRQLQ is a validated quality of life questionnaire to measure the functional impairments that are most troublesome to adult participants with either seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. The miniRQLQ contains 14 items; each item scored on a 7-point scale ranging from 0 [not impaired at all] to 6 [severely impaired]). The overall quality of life score is the average of the all item scores and ranges from 0 (not impaired at all) to 6 (severely impaired), with higher scores indicating more impairment. A negative change in score indicated improvement and a positive change indicated impairment.</description>
          <population>All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="732"/>
                <count group_id="O3" value="800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="732"/>
                    <count group_id="O3" value="800"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="1.435"/>
                    <measurement group_id="O2" value="2.76" spread="1.375"/>
                    <measurement group_id="O3" value="2.73" spread="1.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOS/ET</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="599"/>
                    <count group_id="O3" value="659"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="1.357"/>
                    <measurement group_id="O2" value="-0.99" spread="1.307"/>
                    <measurement group_id="O3" value="-1.01" spread="1.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of informed consent form to 28 days after participants last visit (up to approximately 1 year)</time_frame>
      <desc>Safety evaluable participants defined as those who received at least 1 dose of omalizumab at any point in the study. Safety events collected and recorded during the study were: all serious adverse events, nonserious AEs of special interest, pregnancies, and nonserious AEs causally related to a Genentech product or where causality is unknown. Additional AEs not meeting the protocol-specified criteria listed above were reported during the study and were included in the safety database.</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants With Allergic Asthma (Age 12-17 Years)</title>
          <description>Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
        <group group_id="E2">
          <title>Participants With Allergic Asthma (Age &gt;/=18 Years)</title>
          <description>Adult participants (age &gt;/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
        <group group_id="E3">
          <title>Total Participants With Allergic Asthma</title>
          <description>All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Helicobacter test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Malignant glioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Muscle operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Local reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Mononucleosis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Urticaria chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Foot operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hernia hiatus repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Meningioma surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsorâ€™s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was designed as an observational registry of participants with allergic asthma; but, was later reclassified as an interventional trial because the protocol was amended to include blood draws that were not considered to be standard of care.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

